UPDATE 1-U.S. approves GSK, Xenoport drug for new use

LONDON, June 7 Thu Jun 7, 2012 4:38pm IST

Related Topics

Stocks

   

LONDON, June 7 (Reuters) - GlaxoSmithKline and XenoPort have received approval from the U.S. Food and Drug Administration to sell Horizant to treat post-herpetic neuralgia, the companies said on Thursday.

The medicine is already approved as a treatment for restless legs syndrome. XenoPort will receive a milestone payment of $10 million from GSK following first sales of the drug in its new use.

FILED UNDER: